{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:06:21Z","timestamp":1761930381536,"version":"3.41.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03239-y","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:24:34Z","timestamp":1748492674000},"page":"3505-3527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage\u00a0III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3055-9943","authenticated-orcid":false,"given":"YongJin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1090-0979","authenticated-orcid":false,"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-6565","authenticated-orcid":false,"given":"Kristin J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1372-8525","authenticated-orcid":false,"given":"Mary","family":"DuCharme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0196-2960","authenticated-orcid":false,"given":"Arber","family":"Shehu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanique","family":"Rattigan-Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0498-3708","authenticated-orcid":false,"given":"Kim","family":"Ohaegbulam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"3","key":"3239_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"3239_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824\u201332.","journal-title":"JAMA Oncol"},{"issue":"Suppl 5","key":"3239_CR3","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdq207","volume":"21","author":"L Crin\u00f2","year":"2010","unstructured":"Crin\u00f2 L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v103\u201315.","journal-title":"Ann Oncol"},{"issue":"5","key":"3239_CR4","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/j.cllc.2020.02.025","volume":"21","author":"J Naidoo","year":"2020","unstructured":"Naidoo J, Nishino M, Patel SP, et al. Immune-related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable stage\u00a0III non-small-cell lung cancer. Clin Lung Cancer. 2020;21(5):e435\u201344.","journal-title":"Clin Lung Cancer"},{"key":"3239_CR5","doi-asserted-by":"crossref","unstructured":"Agbarya A, Shalata W, Addeo A, et al. Real-world journey of unresectable stage\u00a0III NSCLC patients: current dilemmas for disease staging and treatment. J Clin Med. 2022;11(6);1738.","DOI":"10.3390\/jcm11061738"},{"issue":"4","key":"3239_CR6","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.3747\/co.27.6047","volume":"27","author":"SJ Seung","year":"2020","unstructured":"Seung SJ, Hurry M, Walton RN, Evans WK. Retrospective cohort study of unresectable stage\u00a0III non-small-cell lung cancer in Canada. Curr Oncol. 2020;27(4):e354\u201360.","journal-title":"Curr Oncol"},{"issue":"3","key":"3239_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtho.2017.11.135","volume":"13","author":"ED Miller","year":"2018","unstructured":"Miller ED, Fisher JL, Haglund KE, et al. The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage\u00a0III non-small cell lung cancer. J Thorac Oncol. 2018;13(3):426\u201335.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"3239_CR8","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Aup\u00e9rin","year":"2010","unstructured":"Aup\u00e9rin A, Le P\u00e9choux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181\u201390.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3239_CR9","doi-asserted-by":"publisher","first-page":"898","DOI":"10.5306\/wjco.v11.i11.898","volume":"11","author":"X Mielgo-Rubio","year":"2020","unstructured":"Mielgo-Rubio X, Rojo F, Mezquita-P\u00e9rez L, et al. Deep diving in the PACIFIC: practical issues in stage\u00a0III non-small cell lung cancer to avoid shipwreck. World J Clin Oncol. 2020;11(11):898\u2013917.","journal-title":"World J Clin Oncol"},{"key":"3239_CR10","doi-asserted-by":"crossref","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623\u201340.","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"3239_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100727","volume":"36","author":"S Verfaillie","year":"2023","unstructured":"Verfaillie S, Lambrecht M, Berkovic P, et al. Treatment of unresectable stage\u00a0III NSCLC: real world cohort study and literature review. Cancer Treat Res Commun. 2023;36:100727.","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"3239_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","volume":"31","author":"K Park","year":"2020","unstructured":"Park K, Vansteenkiste J, Lee KH, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann Oncol. 2020;31(2):191\u2013201.","journal-title":"Ann Oncol"},{"key":"3239_CR13","doi-asserted-by":"publisher","first-page":"175883592211132","DOI":"10.1177\/17588359221113268","volume":"14","author":"J Remon","year":"2022","unstructured":"Remon J, Levy A, Singh P, Hendriks LEL, Aldea M, Arrieta O. Current challenges of unresectable stage\u00a0III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial? Ther Adv Med Oncol. 2022;14:17588359221113268.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"3239_CR14","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.3747\/co.24.3691","volume":"24","author":"JJ Ko","year":"2017","unstructured":"Ko JJ, Tudor R, Li H, et al. Reasons for lack of referral to medical oncology for systemic therapy in stage\u00a0IV non-small-cell lung cancer: comparison of 2003\u20132006 with 2010\u20132011. Curr Oncol. 2017;24(6):e486\u201393.","journal-title":"Curr Oncol"},{"issue":"10","key":"3239_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236503","volume":"15","author":"HY Hung","year":"2020","unstructured":"Hung HY, Tseng YH, Chao HS, et al. Multidisciplinary team discussion results in survival benefit for patients with stage\u00a0III non-small-cell lung cancer. PLoS ONE. 2020;15(10):e0236503.","journal-title":"PLoS ONE"},{"issue":"5","key":"3239_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126547","volume":"10","author":"CC Pan","year":"2015","unstructured":"Pan CC, Kung PT, Wang YH, Chang YC, Wang ST, Tsai WC. Effects of multidisciplinary team care on the survival of patients with different stages of non-small cell lung cancer: a national cohort study. PLoS ONE. 2015;10(5):e0126547.","journal-title":"PLoS ONE"},{"issue":"2","key":"3239_CR17","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1002\/onco.13586","volume":"26","author":"S Popat","year":"2021","unstructured":"Popat S, Navani N, Kerr KM, et al. Navigating diagnostic and treatment decisions in non-small cell lung cancer: expert commentary on the multidisciplinary team approach. Oncologist. 2021;26(2):e306\u201315.","journal-title":"Oncologist"},{"key":"3239_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107414","volume":"187","author":"T Kato","year":"2024","unstructured":"Kato T, Casarini I, Cobo M, et al. Targeted treatment for unresectable EGFR mutation-positive stage\u00a0III non-small cell lung cancer: emerging evidence and future perspectives. Lung Cancer. 2024;187:107414.","journal-title":"Lung Cancer"},{"issue":"24","key":"3239_CR19","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage\u00a0III NSCLC. N Engl J Med. 2018;379(24):2342\u201350.","journal-title":"N Engl J Med"},{"issue":"20","key":"3239_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage\u00a0III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"12","key":"3239_CR21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.21.02528","volume":"40","author":"ME Daly","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, et al. Management of stage\u00a0III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022;40(12):1356\u201384.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3239_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage\u00a0III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3239_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","volume":"18","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Antonia S, Wu YL, et al. Brief report: durvalumab after chemoradiotherapy in unresectable stage\u00a0III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC. J Thorac Oncol. 2023;18(5):657\u201363.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3239_CR24","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.jtho.2023.09.088","volume":"18","author":"S Peters","year":"2023","unstructured":"Peters S, Christoph D, Field J, et al. OA17. 03 Real-world outcomes with durvalumab after chemoradiotherapy in unresectable stage\u00a0III EGFR-mutated NSCLC (PACIFIC-R). J Thorac Oncol. 2023;18(11):S83.","journal-title":"J Thorac Oncol"},{"issue":"48","key":"3239_CR25","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985\u201393.","journal-title":"Oncotarget"},{"issue":"2","key":"3239_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","volume":"142","author":"RP Graham","year":"2018","unstructured":"Graham RP, Treece AL, Lindeman NI, et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med. 2018;142(2):163\u20137.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"3239_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage\u00a0III EGFR-mutated NSCLC. N Engl J Med. 2024;391(7):585\u201397.","journal-title":"N Engl J Med"},{"key":"3239_CR28","doi-asserted-by":"crossref","unstructured":"Lu S, Ahn MJ, Reungwetwattana T, et al. Osimertinib after definitive chemoradiotherapy in unresectable stage\u00a0III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase\u00a0III LAURA study. Ann Oncol. 2024;35(12):1116\u201325.","DOI":"10.1016\/j.annonc.2024.08.2243"},{"issue":"11","key":"3239_CR29","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491\u2013505.","journal-title":"Ann Oncol"},{"issue":"2","key":"3239_CR30","first-page":"255","volume":"28","author":"X Zhang","year":"2022","unstructured":"Zhang X, Beachler DC, Masters E, et al. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States. J Manag Care Spec Pharm. 2022;28(2):255\u201365.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"3239_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40801-022-00344-0","volume":"10","author":"C Molife","year":"2023","unstructured":"Molife C, Cho JM, Lapthorn J, et al. Treatment patterns, clinical outcomes and health care resource utilisation in patients with EGFR-mutated metastatic non-small cell lung cancer: a real-world study in South Korea. Drugs Real World Outcomes. 2023;10(1):131\u201343.","journal-title":"Drugs Real World Outcomes"},{"issue":"3","key":"3239_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s41669-023-00396-0","volume":"7","author":"A Verhoek","year":"2023","unstructured":"Verhoek A, Cheema P, Melosky B, et al. Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer. Pharmacoecon Open. 2023;7(3):455\u201367.","journal-title":"Pharmacoecon Open"},{"key":"3239_CR33","unstructured":"National Cancer Institute. NCI Comorbidity Index Overview: National Cancer Institute; 2014 [updated 2014]. www.healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html. Accessed 11 Aug 2024."},{"issue":"5","key":"3239_CR34","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jtho.2020.12.020","volume":"16","author":"JA Hellyer","year":"2021","unstructured":"Hellyer JA, Aredo JV, Das M, et al. Role of consolidation durvalumab in patients with EGFR- and HER2-mutant unresectable stage\u00a0III NSCLC. J Thorac Oncol. 2021;16(5):868\u201372.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3239_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4143\/crt.2018.125","volume":"51","author":"SE Park","year":"2019","unstructured":"Park SE, Noh JM, Kim YJ, et al. EGFR mutation is associated with short progression-free survival in patients with stage\u00a0III non-squamous cell lung cancer treated with concurrent chemoradiotherapy. Cancer Res Treat. 2019;51(2):493\u2013501.","journal-title":"Cancer Res Treat"},{"issue":"12","key":"3239_CR36","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1097\/JTO.0000000000000675","volume":"10","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Hida T, Oya Y, et al. EGFR mutation impact on definitive concurrent chemoradiation therapy for inoperable stage\u00a0III adenocarcinoma. J Thorac Oncol. 2015;10(12):1720\u20135.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3239_CR37","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022;40(5):492\u2013516.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3239_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.adro.2018.06.003","volume":"3","author":"WCM Schimmel","year":"2018","unstructured":"Schimmel WCM, Gehring K, Eekers DBP, Hanssens PEJ, Sitskoorn MM. Cognitive effects of stereotactic radiosurgery in adult patients with brain metastases: a systematic review. Adv Radiat Oncol. 2018;3(4):568\u201381.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"3239_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","volume":"18","author":"S Popat","year":"2023","unstructured":"Popat S, Ahn MJ, Ekman S, et al. Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies. Target Oncol. 2023;18(1):9\u201324.","journal-title":"Target Oncol"},{"key":"3239_CR40","doi-asserted-by":"crossref","unstructured":"Burney IA, Aal Hamad AH, Hashmi SFA, Ahmad N, Pervez N. Evolution of the management of brain metastases: a bibliometric analysis. Cancers (Basel). 2023;15(23):5570.","DOI":"10.3390\/cancers15235570"},{"issue":"6","key":"3239_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000414","volume":"3","author":"N Girard","year":"2018","unstructured":"Girard N, Cozzone D, de Leotoing L, et al. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. ESMO Open. 2018;3(6):e000414.","journal-title":"ESMO Open"},{"issue":"22","key":"3239_CR42","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2217\/fon-2020-0280","volume":"16","author":"E Nadler","year":"2020","unstructured":"Nadler E, Espirito JL, Pavilack M, Baidoo B, Fernandes A. Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2020;16(22):1575\u201384.","journal-title":"Future Oncol"},{"issue":"11","key":"3239_CR43","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.clon.2017.07.012","volume":"29","author":"I Walraven","year":"2017","unstructured":"Walraven I, Damhuis RA, Ten Berge MG, et al. Treatment variation of sequential versus concurrent chemoradiotherapy in stage\u00a0III non-small cell lung cancer patients in the Netherlands and Belgium. Clin Oncol (R Coll Radiol). 2017;29(11):e177\u201385.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3239_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100460","volume":"29","author":"A Spencer","year":"2021","unstructured":"Spencer A, Williams J, Samuel R, Boon IS, Clarke K, Jain P. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage\u00a0III non-small cell lung cancer: retrospective analysis in a single United Kingdom cancer centre. Cancer Treat Res Commun. 2021;29:100460.","journal-title":"Cancer Treat Res Commun"},{"key":"3239_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.lungcan.2021.10.011","volume":"162","author":"J Evers","year":"2021","unstructured":"Evers J, Hendriks LEL, De Jaeger K, et al. Trends and variations in the treatment of stage\u00a0I-III small cell lung cancer from 2008 to 2019: a nationwide population-based study from the Netherlands. Lung Cancer. 2021;162:61\u201370.","journal-title":"Lung Cancer"},{"key":"3239_CR46","doi-asserted-by":"crossref","unstructured":"Verma V, Simone CB 2nd, Werner-Wasik M. Acute and late toxicities of concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer. Cancers (Basel). 2017;9(9):120.","DOI":"10.3390\/cancers9090120"},{"issue":"2","key":"3239_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1525-1438.2007.00991.x","volume":"18","author":"A Lanceley","year":"2008","unstructured":"Lanceley A, Savage J, Menon U, Jacobs I. Influences on multidisciplinary team decision-making. Int J Gynecol Cancer. 2008;18(2):215\u201322.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"3239_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/00016480600740589","volume":"127","author":"J Stalfors","year":"2007","unstructured":"Stalfors J, Lundberg C, Westin T. Quality assessment of a multidisciplinary tumour meeting for patients with head and neck cancer. Acta Otolaryngol. 2007;127(1):82\u20137.","journal-title":"Acta Otolaryngol"},{"issue":"8","key":"3239_CR49","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1245\/s10434-011-1675-6","volume":"18","author":"BW Lamb","year":"2011","unstructured":"Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol. 2011;18(8):2116\u201325.","journal-title":"Ann Surg Oncol"},{"issue":"suppl_4","key":"3239_CR50","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1\u201321.","journal-title":"Ann Oncol"},{"issue":"10","key":"3239_CR51","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1002\/cncr.22266","volume":"107","author":"EA Newman","year":"2006","unstructured":"Newman EA, Guest AB, Helvie MA, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 2006;107(10):2346\u201351.","journal-title":"Cancer"},{"key":"3239_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100508","volume":"30","author":"J Benet","year":"2022","unstructured":"Benet J, Toffart AC, Brichon PY, et al. Survival of clinical stage\u00a0III NSCLC according to therapeutic strategy: relevance of the tumor board decision in the era of immunotherapy. Cancer Treat Res Commun. 2022;30: 100508.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"3239_CR53","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.21037\/tlcr.2019.11.33","volume":"9","author":"A Kowalczyk","year":"2020","unstructured":"Kowalczyk A, Jassem J. Multidisciplinary team care in advanced lung cancer. Transl Lung Cancer Res. 2020;9(4):1690\u20138.","journal-title":"Transl Lung Cancer Res"},{"key":"3239_CR54","unstructured":"New Estimates Highlight Differences in Growth Between the U.S. Hispanic and Non-Hispanic Populations [press release]. Online: U.S. Census Bureau, 6\/27\/2024 2024."},{"key":"3239_CR55","unstructured":"Keisler-Starkey KaB, Lisa N. Health Insurance Coverage in the United States: 2023. In: Commerce USDo, editor. Online: Commerce, U.S. Dept. of 2024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03239-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T09:02:52Z","timestamp":1750496572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03239-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3239"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03239-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YongJin Kim, Arber Shehu, and Yanique Rattigan-Brown are employees and stockholders of AstraZeneca, PLC. Yong Zhu and Mary DuCharme are employees of Optum, a business unit of UnitedHealth Group, and stockholders of UnitedHealth Group. Kristin J. Moore is a current employee and stockholder of Jazz Pharmaceuticals, PLC. At the time of the study, she was an employee of Optum, a business unit of UnitedHealth Group. She is also a stockholder of UnitedHealth Group. Dan James is an employee of Polaris Biostatistics, Ltd., and received payment from AstraZeneca, PLC, for consultancy work. Kim Ohaegbulam has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval or waiver of approval was not required for this study because the study data were secondary and de-identified in accordance with the US Department of Health and Human Services Privacy Rule\u2019s requirements for de-identification codified at 45 CFR \u00a7 164.514(b).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}